Related references
Note: Only part of the references are listed.Lowering of Amyloid-Beta by β-Secretase Inhibitors - Some Informative Failures
David S. Knopman
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease
David Henley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease
Michael F. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Alzheimer's Amyloid-beta is an Antimicrobial Peptide: A Review of the Evidence
Maya L. Gosztyla et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Alzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection (vol 99, pg 56, 2018)
William A. Eimer et al.
NEURON (2018)
Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606
Steven L. Wagner et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease
Cheng Zhang et al.
ALZHEIMERS & DEMENTIA (2016)
Astrogliosis
Michael V. Sofroniew
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2015)
Effect of Potent γ-Secretase Modulator in Human Neurons Derived From Multiple Presenilin 1-Induced Pluripotent Stem Cell Mutant Carriers
Qing Liu et al.
JAMA NEUROLOGY (2014)
A fast growing spectrum of biological functions of γ-secretase in development and disease
Nathalie Jurisch-Yaksi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2013)
Differential Relationships of Reactive Astrocytes and Microglia to Fibrillar Amyloid Deposits in Alzheimer Disease
Alberto Serrano-Pozo et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2013)
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Potential Use of γ-Secretase Modulators in the Treatment of Alzheimer Disease
Steven L. Wagner et al.
ARCHIVES OF NEUROLOGY (2012)
Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
Vladimir Coric et al.
ARCHIVES OF NEUROLOGY (2012)
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study
Eric M. Reiman et al.
LANCET NEUROLOGY (2012)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
Randall J. Bateman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Endogenous Amyloid-β is Necessary for Hippocampal Synaptic Plasticity and Memory
Daniela Puzzo et al.
ANNALS OF NEUROLOGY (2011)
Neuropathological Alterations in Alzheimer Disease
Alberto Serrano-Pozo et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2011)
Inflammation in transgenic mouse models of neurodegenerative disorders
Claudia Schwab et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2010)
Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease
Maria Z. Kounnas et al.
NEURON (2010)
And four equals one: Presenilin takes the γ-secretase role by itself
Christian B. Lessard et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Activation and intrinsic γ-secretase activity of presenilin 1
Kwangwook Ahn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer's Disease
Robert L. Martone et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Chemical Cross-linking Provides a Model of the γ-Secretase Complex Subunit Architecture and Evidence for Close Proximity of the C-terminal Fragment of Presenilin with APH-1
Harald Steiner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL/PS1M146L and APP751SL/PS1M146L transgenic mice
BPF Rutten et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective
RE Tanzi et al.
CELL (2005)
The microglial phagocytic role with specific plaque types in the Alzheimer disease brain
MR D'Andrea et al.
NEUROBIOLOGY OF AGING (2004)
The presenilin C-terminus is required for ER-retention, nicastrin-binding and γ-secretase activity
C Kaether et al.
EMBO JOURNAL (2004)
Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches
J Tsai et al.
NATURE NEUROSCIENCE (2004)
The role of presenilin cofactors in the γ-secretase complex
N Takasugi et al.
NATURE (2003)
Alzheimer's disease: Genes, proteins, and therapy
DJ Selkoe
PHYSIOLOGICAL REVIEWS (2001)
Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease
Y Matsuoka et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Aspartate mutations in presenilin and γ-secretase inhibitors both impair Notch1 proteolysis and nuclear translocation with relative preservation of Notch1 signaling
O Berezovska et al.
JOURNAL OF NEUROCHEMISTRY (2000)
Age-related amyloid β deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid β precursor protein Swedish mutant is not associated with global neuronal loss
A Takeuchi et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
